Corbus Pharmaceuticals Holdings, Inc. - 8-K Filing
Corbus Pharmaceuticals reported a Q1 2026 net loss of $23.0 million, or $1.23 per share, compared to $17.0 million, or $1.39 per share in the same period last year. The company had $138.2 million in cash and equivalents as of March 31, 2026, which is expected to fund operations into 2028. It also announced key updates on its drug candidates CRB-701 (oncology) and CRB-913 (obesity), including FDA alignment for registration trials and enrollment completion in the CANYON-1 study. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $CRBP